A5051708137- Blood Pressure and Hypertension Studies
- Dialysis and Renal Disease Management
- Hormonal Regulation and Hypertension
- Hemodynamic Monitoring and Therapy
- Chronic Kidney Disease and Diabetes
- Diabetes Treatment and Management
- Erythropoietin and Anemia Treatment
- Cardiovascular Health and Disease Prevention
- Heart Failure Treatment and Management
- Iron Metabolism and Disorders
- Sodium Intake and Health
- Hemoglobinopathies and Related Disorders
- Heart Rate Variability and Autonomic Control
- Potassium and Related Disorders
- Renal function and acid-base balance
- Cardiovascular Function and Risk Factors
- Renal and Vascular Pathologies
- Eicosanoids and Hypertension Pharmacology
- Electrolyte and hormonal disorders
- Central Venous Catheters and Hemodialysis
- Cardiac Imaging and Diagnostics
- Cardiac, Anesthesia and Surgical Outcomes
- Muscle and Compartmental Disorders
- Renal Diseases and Glomerulopathies
- Pancreatic function and diabetes
Indiana University – Purdue University Indianapolis
2016-2025
Richard L. Roudebush VA Medical Center
2016-2025
Indiana University School of Medicine
2016-2025
Vanderbilt University Medical Center
2006-2025
Indiana University Indianapolis
1999-2023
Max Super Speciality Hospital
2022
Kobe University
2022
Boise Kidney & Hypertension Institute
2022
Karolinska Institutet
2022
Indiana University
2008-2021
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials inhibitors sodium–glucose cotransporter (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type diabetes.
The complementary studies FIDELIO-DKD and FIGARO-DKD in patients with type 2 diabetes chronic kidney disease (CKD) examined cardiovascular outcomes different, overlapping stages of CKD. purpose the FIDELITY analysis was to perform an individual patient-level prespecified pooled efficacy safety across a broad spectrum CKD provide more robust estimates finerenone compared placebo.For this analysis, two phase III, multicentre, double-blind trials involving diabetes, randomized 1:1 or placebo,...
<h3>Context</h3>Vitamin D is associated with decreased cardiovascular-related morbidity and mortality, possibly by modifying cardiac structure function, yet firm evidence for either remains lacking.<h3>Objective</h3>To determine the effects of an active vitamin compound, paricalcitol, on left ventricular mass over 48 weeks in patients estimated glomerular filtration rate 15 to 60 mL/min/1.73 m<sup>2</sup>.<h3>Design, Setting, Participants</h3>Multinational, double-blind, randomized...
Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) severely elevated albuminuria and type 2 diabetes. The use of finerenone diabetes wider range CKD is unclear.
<h3>Importance</h3> Although strain on hospital capacity has been associated with increased mortality in nonpandemic settings, studies are needed to examine the association between coronavirus disease 2019 (COVID-19) critical care and mortality. <h3>Objective</h3> To whether COVID-19 was intensive unit (ICU) strain. <h3>Design, Setting, Participants</h3> This cohort study conducted among veterans COVID-19, as confirmed by polymerase chain reaction or antigen testing laboratory from March...
Vitamin D receptor activation is associated with improved survival in patients chronic kidney disease, but the mechanism of this benefit unclear. To better understand effects vitamin on endothelial function, blood pressure, albuminuria, and inflammation disease (2 stage 2, remaining 3), we conducted a pilot trial 24 who were randomly allocated equally to 3 groups receive 0, 1, or 2 μg paricalcitol, analog, orally for 1 month. Placebo-corrected change flow mediated dilatation 1-μg dose was...
<h3>Background</h3> Ambulatory blood pressure (BP) measurement allows a better risk stratification in essential hypertension compared with office measurement, but its prognostic role nondialysis chronic kidney disease has been poorly investigated. <h3>Methods</h3> The of daytime and nighttime systolic BP (SBP) diastolic (DBP) comparison measurements was evaluated 436 consecutive patients disease. Primary end points were time to renal death (end-stage or death) fatal nonfatal cardiovascular...
The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression Diabetic Disease) evaluated the effect of nonsteroidal, selective mineralocorticoid receptor antagonist finerenone on kidney cardiovascular outcomes patients with chronic disease type 2 diabetes optimized renin-angiotensin system blockade. Compared placebo, reduced composite outcomes. We report individual without history atherosclerotic (CVD). This randomized, double-blind, placebo-controlled included urine...
<b><i>Background:</i></b> People with diabetes and kidney disease have a high risk of cardiovascular events progression disease. Sodium glucose co-transporter 2 inhibitors lower plasma by reducing the uptake filtered in tubule, leading to increased urinary excretion. They been repeatedly shown induce modest natriuresis reduce HbA1c, blood pressure, weight, albuminuria patients type diabetes. However, effects these agents on not extensively studied established...
Little evidence has been available to support the use of thiazide diuretics treat hypertension in patients with advanced chronic kidney disease.We randomly assigned stage 4 disease and poorly controlled hypertension, as confirmed by 24-hour ambulatory blood-pressure monitoring, a 1:1 ratio receive chlorthalidone at an initial dose 12.5 mg per day, increases every weeks if needed maximum 50 or placebo; randomization was stratified according previous loop diuretics. The primary outcome change...
Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, a class of drugs that stabilize HIF and stimulate erythropoietin red-cell production.
Chronic kidney disease and type 2 diabetes are independently associated with heart failure (HF), a leading cause of morbidity mortality. In the FIDELIO-DKD (Finerenone in Reducing Kidney Failure Disease Progression Diabetic Disease) FIGARO-DKD Cardiovascular Mortality Morbidity trials, finerenone (a selective, nonsteroidal mineralocorticoid receptor antagonist) improved cardiovascular outcomes patients albuminuric chronic diabetes. These prespecified analyses from assessed effect on...
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, a class of compounds that stimulate endogenous erythropoietin production.We conducted two randomized, open-label, noninferiority phase 3 trials to evaluate the safety and efficacy vadadustat, as compared with darbepoetin alfa, in patients anemia incident or prevalent dialysis-dependent chronic kidney disease (DD-CKD). The primary end point, assessed time-to-event analysis, was first occurrence major adverse...
The present paper provides an update of previous recommendations on Home Blood Pressure Monitoring from the European Society Hypertension (ESH) Working Group and Cardiovascular Variability sequentially published in years 2000, 2008 2010. This has taken into account new evidence this field, including a recent statement by American Heart association, as well technological developments, which have occurred over past 20 years. document been developed same ESH with inputs international team...
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at risk of atrial fibrillation or flutter (AFF) due to cardiac remodeling complications. Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, inhibited in preclinical models. This work aims examine the effect finerenone on new-onset AFF cardiorenal effects by history Finerenone Reducing Kidney Failure Disease Progression Diabetic (FIDELIO-DKD) study. CKD T2D were randomized (1:1) placebo....
FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone patients with CKD type 2 diabetes (T2D). This analysis explores impact of use sodium-glucose cotransporter-2 inhibitor (SGLT-2i) on treatment effect finerenone.Patients (N = 5674) T2D, urine albumin-to-creatinine ratio (UACR) 30 to 5000 mg/g estimated glomerular filtration rate (eGFR) 25 <75 ml/min...
Abstract Aims Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use agents that block renin–angiotensin–aldosterone system, particularly in patients with chronic kidney disease (CKD). In CKD, sodium‒glucose cotransporter (SGLT2) inhibitors provide cardiorenal protection, but whether they affect risk hyperkalaemia remains uncertain. Methods results The CREDENCE trial randomized 4401 participants T2DM CKD to SGLT2 inhibitor canagliflozin or...
BACKGROUND: Sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid antagonist (ns-MRA) finerenone all individually reduce cardiovascular, kidney, mortality outcomes in patients with type diabetes albuminuria. However, lifetime benefits of combination therapy these medicines are not known. METHODS: We used data from SGLT2i trials (CANVAS [Canagliflozin Cardiovascular Assessment] CREDENCE Renal Events...